Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3956635 | 1.00 | CYP3A4 (0.63) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL5901407 | 0.91 | CYP3A4 (0.53) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL3960415 | 0.90 | CYP3A4 (0.51) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL3959888 | 0.87 | CYP3A4 (0.51) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL13647529 | 0.87 | CYP3A4 (0.67) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4336874 | 0.86 | CYP3A4 (0.50) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL3964629 | 0.86 | CYP3A4 (0.49) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL3965110 | 0.83 | CYP3A4 (0.47) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4329615 | 0.83 | CYP3A4 (0.66) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL5901697 | 0.83 | CYP3A4 (0.66) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601721-B2 | Substituted heterocyclic compounds | GILEAD PALO ALTO, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2009-02-26 | — | — | US | disclosed |
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2009-02-26 | — | — | US | disclosed |
| US-7452889-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452889-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080070927-A1 | Substituted Heterocyclic Compounds | ZABLOCKI JEFF | 2008-03-20 | — | — | US | disclosed |
| US-20080032993-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2008-02-07 | — | — | US | disclosed |
| US-20080032993-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2008-02-07 | — | — | US | disclosed |
| US-7271169-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7262198-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20060229317-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2006-10-12 | — | — | US | disclosed |
| US-7115610-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-7026321-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| WO-2006029179-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1583751-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISEASES | CV THERAPEUTICS, INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050197346-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2005-09-08 | — | — | US | disclosed |
| WO-2005061470-A1 | 1-AKAN-2-OL SUBSTITUTED PIPERAZINE AND PIPERIDINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005000826-A1 | UREA DERIVATIVES OF PIPERAZINES AND PIPERIDINES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040186109-A1 | piperazine derivatives, e.g., (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-({5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]propan-2-ol; treating diabetes, arrhythmia, intermittent claudication, angina, congestive heart disease, and myocardial infarction | CV THERAPEUTICS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004069818-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISEASES | CV THERAPEUTICS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229317-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | CYP3A4 608/4885CYP1A2 530/4885CYP2C9 357/4885 |
| US-20080070927-A1 | Substituted Heterocyclic Compounds | KCNJ2, KCNH1, KCNJ1 | CYP3A4 1454/4885CYP1A2 1155/4885CYP2C9 2053/4885 |
| US-20040186109-A1 | piperazine derivatives, e.g., (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-({5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]propan-2-ol; treating diabetes, arrhythmia, intermittent claudication, angina, congestive heart disease, and myocardial infarction | KCNJ2, PPARA, PPARD | CYP3A4 1199/4885CYP1A2 757/4885CYP2C9 1407/4885 |
| US-20080032993-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, SDHA, COQ8A | CYP3A4 608/4885CYP1A2 530/4885CYP2C9 357/4885 |
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, SDHA, COQ8A | CYP3A4 608/4885CYP1A2 530/4885CYP2C9 357/4885 |
| US-20050197346-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | CYP3A4 608/4885CYP1A2 530/4885CYP2C9 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.